title: Trans-arterial hepatic radioembolisation of yttrium-90 microspheres.
abstract: The liver represents a frequent site for metastatic disease, in addition to being a site for primary cancer. Hepatic metastases from certain neoplasms, such as colon, neuroendocrine, melanoma and gastrointestinal stromal tumour have a distinct predilection to metastasize the liver, which in many cases may represent the only or the dominant site of disease. In these circumstances, cytoreduction via surgery or in situ ablative techniques aims to influence the natural history of the disease progression and improve clinical outcomes.Liver directed therapy utilising yttrium-90 microspheres represents a recently introduced in situ multidisciplinary cancer therapy that has caught the attention of many physicians faced with the challenges of treating these complex patients. Although similar to other forms of trans-arterial liver directed therapy, there are discrete differences and potentially fatal treatment consequences unique to this therapy. This objective of this review article is to provide the reader a basis for understanding the therapeutic principles, patient exclusion criteria, pre and post therapy investigations and salient clinical results in the two most commonly treated disease types; metastatic colorectal cancer and hepatocellular cancer.
authors: Interventional Radiology Section, University of Texas, Houston, United States.
authors: R
authors: R
authors: Murthy
authors: A
authors: A
authors: Habbu
authors: R
authors: R
authors: Salem
references: Ann Oncol. 2001 Dec;12(12):1711-20
references: 11843249
references: Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):815-20
references: 12029557
references: J Nucl Med. 2000 Oct;41(10):1673-81
references: 11037997
references: J Gastrointest Surg. 2006 Mar;10(3):413-6
references: 16504888
references: Br J Cancer. 1994 Nov;70(5):994-9
references: 7947110
references: Med Phys. 2004 Sep;31(9):2449-53
references: 15487724
references: J Gastrointest Surg. 2001 May-Jun;5(3):294-302
references: 11360053
references: Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):463-7
references: 2061122
references: Ann Intern Med. 2003 Nov 18;139(10):817-23
references: 14623619
references: CA Cancer J Clin. 1999 Jan-Feb;49(1):6-7
references: 10200774
references: Dis Colon Rectum. 1979 Sep;22(6):371-5
references: 498890
references: Arch Surg. 1990 Aug;125(8):1022-7
references: 2143063
references: J Nucl Med. 1994 Oct;35(10):1637-44
references: 7931662
references: Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1552-63
references: 15590187
references: Int J Cancer. 1999 Sep 24;83(1):18-29
references: 10449602
references: Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):810-21
references: 12095546
references: Liver Transpl. 2004 Feb;10(2 Suppl 1):S107-10
references: 14762849
references: Gastroenterology. 2004 Nov;127(5 Suppl 1):S194-205
references: 15508085
references: Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):919-24
references: 7591903
references: Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7
references: 15166961
references: J Surg Oncol. 2004 Nov 1;88(2):78-85
references: 15499601
references: J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):195-203
references: 15713920
references: J Clin Oncol. 1997 Mar;15(3):938-46
references: 9060531
references: Ann Surg. 2004 Aug;240(2):299-305
references: 15273555
references: J Surg Oncol. 1989 Nov;42(3):192-6
references: 2811384
references: Radiology. 1982 Mar;142(3):783-6
references: 7063703
references: Cancer Treat Rep. 1978 Oct;62(10):1509-12
references: 709552
references: J Vasc Interv Radiol. 2005 Jul;16(7):937-45
references: 16002501
references: Aust N Z J Surg. 1992 Feb;62(2):105-10
references: 1586298
references: Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):583-92
references: 9486608
references: Radiology. 1993 Apr;187(1):125-8
references: 8451398